{"schema_version":"secwatch.filing_event.v1","accession":"0000816956-25-000026","form_type":"8-K","ticker":"CNMD","cik":"0000816956","company_name":"CONMED Corp","filed_at":"2025-07-30T23:59:59+00:00","discovered_at":"2026-05-14T18:02:46.440994+00:00","generated_at":"2026-05-17T23:21:35.402661+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"CONMED Q2 adj EPS $1.15 beats; raises FY2025 revenue and adj EPS guidance","bullets":["Q2 sales $342.3M (+3.1% YoY); GAAP EPS $0.69 (down from $0.96), adj EPS $1.15 (up from $0.98).","Single-use products +6.6% to $297.8M; capital products -15.5% to $44.5M.","FY revenue guidance raised to $1.356B-1.378B; adj EPS raised to $4.40-4.55 (prior $4.31-4.46).","Company estimates ~$0.09 EPS headwind from tariffs in H2 2025.","Operational optimization consulting fees $7.6M in Q2; exec transition costs $12.2M YTD."],"urls":{"canonical":"https://secwatch.observer/filing/0000816956-25-000026","json":"https://secwatch.observer/filing/0000816956-25-000026.json","markdown":"https://secwatch.observer/filing/0000816956-25-000026.md","text":"https://secwatch.observer/filing/0000816956-25-000026.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/816956/000081695625000026/0000816956-25-000026-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/816956/000081695625000026/cnmd-20250730.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-17T23:21:35.402661+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}